TRPV1 Agonist Prodrugs for Aqueous Solubility and Controlled Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current TRPV1 agonists like capsaicin have limited water solubility, causing irritation and requiring non-aqueous formulations, and their prolonged use leads to desensitization, reducing pain relief efficacy, while existing solutions fail to provide controlled release and solubility in aqueous sterile injectable formulations.
Innovation Solution
Development of water-soluble TRPV1 agonist prodrugs with modified chemical structures for increased hydrophilicity, allowing pH-controlled cyclization-release reactions for controlled bioavailability and reduced pungency, enabling rapid or delayed release tailored for specific pharmacological effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TRPV1 agonists like capsaicin are used, then pain relief efficacy is achieved, but water solubility is limited and irritation occurs
Solution Approach 1:
The patent introduces prodrugs as intermediary compounds that convert TRPV1 agonists into water-soluble forms. These prodrugs act as mediators between the active drug and the body's aqueous environment, enabling dissolution in water-based formulations while reducing direct irritation. The prodrugs are designed to be metabolically converted into the active TRPV1 agonist at the site of action, thus providing pain relief without the direct irritation caused by the parent compound.
Solution Approach 2:
The patent modifies the chemical structure of TRPV1 agonists by changing physical and chemical parameters to enhance water solubility. Specific structural modifications include adding hydrophilic groups, altering fatty acid chains, and creating prodrug formulations with different molecular properties. These parameter changes enable the compounds to dissolve in aqueous sterile injectable formulations while maintaining their TRPV1 agonist activity.
2Duration of action of moving object
If TRPV1 agonists are used for prolonged pain relief, then pain management duration is extended, but desensitization occurs reducing efficacy
Solution Approach 1:
The patent employs prodrugs with controlled release characteristics that dynamically adjust the delivery of active TRPV1 agonist. The prodrugs are designed to release the active compound at controlled rates, providing sustained pain relief while avoiding the rapid saturation and desensitization that occurs with direct administration of the parent drug. This dynamic release mechanism maintains effective concentrations over extended periods without triggering desensitization.
Solution Approach 2:
The patent uses prodrugs that undergo preliminary metabolic conversion before exerting their pharmacological effect. This preliminary action of converting the prodrug to the active form occurs gradually and controlled manner, preventing sudden high concentrations that would cause desensitization. The gradual activation allows for sustained pain relief over time while maintaining efficacy through controlled bioavailability.
3Stability of the object's composition
If non-aqueous formulations are used to improve solubility, then compound stability is maintained, but formulation complexity increases
Solution Approach 1:
The patent changes the chemical parameters of the compound by creating prodrugs with modified molecular structures that inherently possess water solubility. This eliminates the need for complex non-aqueous formulation systems. The prodrugs are designed to dissolve directly in water-based sterile injectable formulations, simplifying the formulation process while maintaining compound stability through appropriate chemical modification and selection of stable prodrug moieties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The prodrugs provide improved water solubility and reduced irritation, allowing for effective pain relief with controlled release, eliminating the need for specialized formulations and reducing acute pungency, while maintaining efficacy and stability in physiological conditions.
Implementation Method 1
pH-controlled cyclization-release reactions for controlled bioavailability and reduced pungency
Data Source
AI summary
Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential vanilloid 1 receptor (TRPV1) activity.